New patent filings target one of weight loss medicine’s biggest challenges: keeping muscle while shedding pounds.
By securing patent claims across both peptide constructs (EL-22) and bioengineered microorganisms (EL-32), is the company trying to build an ironclad monopoly on the entire muscle-preservation side of the weight-loss industry?
That may be a provocative way of framing it, but it captures a growing reality in the obesity-treatment market: the battle is no longer just about helping people lose weight, but about helping them hold on to what matters while they do it.
PMGC Holdings announced that its subsidiary, NorthStrive Biosciences, has filed two new US patent applications that expand its EL-22 and EL-32 programs into potential human pharmaceutical applications. The filings focus on preserving lean muscle mass in people undergoing weight-loss treatment, including those using GLP-1 drugs and newer obesity therapies [1]. It’s an attempt to stake out territory in what many believe could become one of the most important adjacent markets created by the GLP-1 revolution.
The problem nobody was talking about
The first wave of GLP-1 success stories focused on the number on the scale. Patients lost weight. Investors celebrated. Drugmakers raced to develop the next generation of treatments. But as the market matured, another conversation began to emerge.
When people lose substantial amounts of weight, they do not lose fat alone. Some of that weight can come from lean muscle tissue – the very tissue that helps us move, stay metabolically healthy and maintain independence as we age. Think of it like renovating a house. If the goal is to remove unwanted clutter, nobody wants to accidentally tear out structural support beams in the process.
That growing concern has turned muscle preservation into one of the most closely watched opportunities in obesity medicine. NorthStrive’s latest filings appear designed to address exactly that challenge.
The company’s patent applications, assigned numbers 19/709,895 for EL-22 and 19/709,950 for EL-32, cover potential uses of the technologies in people experiencing muscle loss linked to obesity treatment, aging-related muscle decline, malnutrition, physical inactivity and certain neurological conditions.
The science behind the two programs differs, but the objective is similar. EL-22 is based on peptide technology, while EL-32 explores a platform involving engineered microorganisms, including strains of beneficial bacteria.
For most patients, the technical distinctions may matter less than the practical goal. Both approaches are being developed with the aim of helping preserve lean muscle mass during periods when the body might otherwise lose it.
The applications also include claims covering use alongside GLP-1 therapies, as well as newer dual- and triple-action obesity treatments targeting GLP-1, GIP and glucagon pathways. In other words, NorthStrive is not trying to replace weight-loss drugs; it appears to be positioning itself as a potential companion to them.
Investors should pay attention
What stands out is not just what NorthStrive is patenting, but how broadly it is patenting. The filings include multiple product formats and delivery methods, ranging from oral and injectable approaches to nasal and topical options. They also cover combination strategies involving apelin and ursolic acid, compounds that have been associated with muscle support. From an intellectual property perspective, the strategy resembles placing markers across several routes to the same destination.
Whether any single approach ultimately succeeds remains uncertain. Patent filings are early-stage developments, not proof that a therapy works or will reach the market. Still, the breadth of the claims suggests the company sees muscle preservation as more than a scientific question. It sees it as a commercial category in its own right.
For years, obesity drug development has largely focused on maximizing weight loss. The conversation is now becoming more sophisticated. Clinicians, researchers and investors are increasingly asking what kind of weight is being lost and what happens to the body afterward.
Now, for the longevity field, this matters because muscle is about much more than appearance. Muscle strength and muscle mass are closely tied to mobility, resilience and quality of life later in life. In many ways, muscle functions as a reserve account for healthy aging. The more of it we maintain, the better positioned we may be to withstand illness, injury and the physiological stresses that come with growing older. That makes the rise of muscle-preservation technologies one of the more interesting developments to emerge from the GLP-1 boom.
The first chapter of the obesity revolution was about shrinking waistlines. The next may be about protecting the function. And that brings us back to the original question. Is NorthStrive attempting an intellectual-property land grab around muscle preservation?
It is too early to know whether EL-22 or EL-32 will become commercial products. What is clear is that the company is positioning itself where it believes the market is heading. As obesity treatment evolves beyond simple weight loss and toward healthier body composition, preserving muscle may become one of the industry’s most valuable prizes – and one of longevity medicine’s most important goals.
